Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Depreciation & Amortization (CF) (2016 - 2025)

Rockwell Medical (RMTI) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $544000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) changed 0.18% year-over-year to $544000.0, compared with a TTM value of $2.2 million through Sep 2025, changed 0.09%, and an annual FY2024 reading of $2.2 million, up 50.97% over the prior year.
  • Depreciation & Amortization (CF) was $544000.0 for Q3 2025 at Rockwell Medical, down from $563000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $564000.0 in Q3 2023 and bottomed at $133000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $342842.1, with a median of $202000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 39.55% in 2021, then soared 294.41% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $133000.0 in 2021, then rose by 15.79% to $154000.0 in 2022, then surged by 257.14% to $550000.0 in 2023, then fell by 1.27% to $543000.0 in 2024, then grew by 0.18% to $544000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for RMTI at $544000.0 in Q3 2025, $563000.0 in Q2 2025, and $539000.0 in Q1 2025.